Skip to content
Home
Edith M. Lord, Ph.D.

Edith M. Lord, Ph.D.

Contact

Office (585) 275-5855

Looking for more Information?

Visit my lab website to learn more about my research, collaborators, latest news, etc.

Visit Research Lab Website

About Me

Dr. Edith Lord is a Professor of Microbiology & Immunology and Oncology. Dr. Lord received her BA degree in microbiology from the University of Kansas in 1970 and a Ph.D degree in immunology from the University of California at San Diego in 1975. She was a postdoctoral fellow at the University of ...
Dr. Edith Lord is a Professor of Microbiology & Immunology and Oncology. Dr. Lord received her BA degree in microbiology from the University of Kansas in 1970 and a Ph.D degree in immunology from the University of California at San Diego in 1975. She was a postdoctoral fellow at the University of California at San Francisco. As a faculty member since 1976, Dr. Lord has demonstrated excellence as a scientist and dedication to the training of graduate students and postdoctoral fellows.

From 2006-2008, Dr. Lord led the graduate program in the Department of Microbiology and Immunology. She was the Senior Associate Dean for Graduate Education and Postdoctoral Affairs at the School of Medicine and Dentistry from 2008-2018.

In her research, Dr. Lord focuses on the immune responses that can control tumor development and how immune cells function within the unique microenvironment of growing tumors. She has published, as author and co-author, more than 130 scientific articles and continues her passion for research today.

Faculty Appointments

Professor Emerita - Department of Microbiology and Immunology (SMD)

Credentials

Education

PhD | Univ of Cal San Diego. Immunology. 1975

BA | University of Kansas. Microbiology. 1970

Awards

Graduate Student Society Advocacy Award. 2018

Research

Patents

Detection of Hypoxia with Reagents Containing 2-Nitroimidazole Compounds and Methods of Making such Reagents.

Issue date: July 30, 1996

Patent #: 5,540,908

Country: United States

Inventors: Cameron J Koch, Edith M Lord

Detection of Hypoxia

Issue date: December 01, 1998

Patent #: 5,843,404

Country: United States

Inventors: Cameron J Koch, Edith M Lord

Method of Monitoring Exposure to Bowman Birk Inhibitor Using Monoclonal Antibodies Against Bowman Birk Inhibitor Metabolites

Issue date: April 08, 1997

Patent #: 5,618,679

Country: United States

Inventors: Ann R Kennedy, Cameron J Koch, Edith M Lord, Xingsheng Wan

Monoclonal Antibodies Differentially Reactive with Native and Reductively Modified Bowman-Birk Protease Inhibitor

Issue date: April 01, 1997

Patent #: 5,616,492

Country: United States

Inventors: Ann R Kennedy, Cameron J Koch, Edith M Lord, Xingsheng Wan

Serum Free Cell Culture Medium

Issue date: March 28, 1989

Patent #: 4,816,401

Country: United States

Inventors: Edith M Lord

Publications

Journal Articles

Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer.

Hughson AL, Hannon G, Salama NA, Vrooman TG, Stockwell CA, Mills BN, Garrett-Larsen J, Qiu H, Katerji R, Benoodt L, Johnston CJ, Murphy JD, Kruger E, Ye J, Gavras NW, Keeley DC, Qin SS, Lesch ML, Muhitch JB, Love TMT, Calvi LM, Lord EM, Luheshi N, Elyes J, Linehan DC, Gerber SA

Molecular therapy. Nucleic acids.. 2024 December 1035 (4):102350. Epub 09/30/2024.

New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy.

Uccello TP, Lesch ML, Kintzel SA, Gradzewicz LB, Lamrous L, Murphy SP, Fleming FJ, Mills BN, Murphy JD, Hughson A, Hannon G, Garrett-Larsen J, Qiu H, Drage MG, Ye J, Gavras NW, Keeley DC, Love TMT, Repasky EA, Lord EM, Linehan DC, Gerber SA

Cell death & disease.. 2023 July 2614 (7):470. Epub 07/26/2023.

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.

Ye J, Gavras NW, Keeley DC, Hughson AL, Hannon G, Vrooman TG, Lesch ML, Johnston CJ, Lord EM, Belt BA, Linehan DC, Eyles J, Gerber SA

Journal for immunotherapy of cancer.. 2023 May 11 (5)Epub 1900 01 01.

Radiation Therapy Exacerbates Tumor-Promoting Innervation and Nerve Signaling in Rectal Cancer.

Uccello TP, Lecsh ML, Ullman NA, Kintzel SA, Gradzewicz LB, Velagaleti T, Fleming FJ, Mills BN, Murphy JD, Garrett-Larsen J, Qiu H, Drage MG, Ye J, Gavras NW, Johnston CJ, Love TMT, Repasky EA, Linehan DC, Lord EM, Gerber SA

International journal of radiation oncology, biology, physics.. 2023 March 1115 (3):733-745. Epub 10/04/2022.

Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.

Battaglia NG, Murphy JD, Uccello TP, Hughson A, Gavras NW, Caldon JJ, Gerber SA, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2022 August 1209 (3):629-640. Epub 07/15/2022.

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.

Ye J, Mills BN, Qin SS, Garrett-Larsen J, Murphy JD, Uccello TP, Han BJ, Vrooman TG, Johnston CJ, Lord EM, Belt BA, Linehan DC, Gerber SA

Journal for immunotherapy of cancer.. 2022 July 10 (7)Epub 1900 01 01.

Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.

Ortiz-Bonilla CJ, Uccello TP, Gerber SA, Lord EM, Messing EM, Lee YF

International journal of molecular sciences.. 2022 March 823 (6)Epub 03/08/2022.

Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.

Mills BN, Qiu H, Drage MG, Chen C, Mathew JS, Garrett-Larsen J, Ye J, Uccello TP, Murphy JD, Belt BA, Lord EM, Katz AW, Linehan DC, Gerber SA

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2022 January 128 (1):150-162. Epub 12/03/2021.

Development of an Orthotopic Murine Model of Rectal Cancer in Conjunction With Targeted Short-Course Radiation Therapy.

Uccello TP, Kintzel SA, Mills BN, Murphy JD, Garrett-Larsen J, Battaglia NG, Rodriguez CJ, Drage MG, Ye J, Love TMT, Johnston CJ, Repasky EA, Qiu H, Linehan DC, Lord EM, Gerber SA

Advances in radiation oncology.. 2022 7 (2):100867. Epub 12/09/2021.

Coadministration of a Clinically Relevant Dexamethasone Dosage With Ablative Radiation Therapy Reduces Peripheral Lymphocytes But Does Not Alter In Vivo Intratumoral Lymphocyte Phenotype or Inhibit Efficacy of Radiation Therapy in a Murine Colorectal Tumor Model.

Battaglia NG, Uccello TP, Hughson A, Garrett-Larsen J, Caldon JJ, Qiu H, Gerber SA, Lord EM

International journal of radiation oncology, biology, physics.. 2021 September 1111 (1):284-296. Epub 04/30/2021.

Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model.

Qin SS, Han BJ, Williams A, Jackson KM, Jewell R, Chacon AC, Lord EM, Linehan DC, Kim M, Reuben A, Gerber SA, Prieto PA

Cancers.. 2021 May 1113 (10)Epub 05/11/2021.

Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.

Han BJ, Murphy JD, Qin S, Ye J, Uccello TP, Garrett-Larsen J, Belt BA, Prieto PA, Egilmez NK, Lord EM, Linehan DC, Mills BN, Gerber SA

Immunological investigations.. 2020 October 49 (7):808-823. Epub 06/04/2020.

Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.

Ye J, Mills BN, Zhao T, Han BJ, Murphy JD, Patel AP, Johnston CJ, Lord EM, Belt BA, Linehan DC, Gerber SA

Cancer immunology research.. 2020 January 8 (1):94-107. Epub 11/12/2019.

Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.

Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qiu H, Patel A, Figueroa NM, Johnston CJ, Prieto PA, Egilmez NK, Belt BA, Lord EM, Linehan DC, Gerber SA

Cell reports.. 2019 October 829 (2):406-421.e5. Epub 1900 01 01.

Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation.

MacDonald CR, Bucsek MJ, Qiao G, Chen M, Evans L, Greenberg DJ, Uccello TP, Battaglia NG, Hylander BL, Singh AK, Lord EM, Gerber SA, Repasky EA

Radiation research.. 2019 June 191 (6):585-589. Epub 04/25/2019.

Intratumoral Hypoxia Reduces IFN-?-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model.

Murthy A, Gerber SA, Koch CJ, Lord EM

ImmunoHorizons.. 2019 April 293 (4):149-160. Epub 04/29/2019.

Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes.

Connolly KA, Belt BA, Figueroa NM, Murthy A, Patel A, Kim M, Lord EM, Linehan DC, Gerber SA

Oncotarget.. 2016 December 277 (52):86522-86535. Epub 1900 01 01.

Total-Body Irradiation Exacerbates Dissemination of Cutaneous Candida Albicans Infection.

Barlow ML, Cummings RJ, Pentland AP, Love TM, Haidaris CG, Ryan JL, Lord EM, Gerber SA

Radiation research.. 2016 November 186 (5):436-446. Epub 10/06/2016.

Whole mount immunofluorescence analysis of placentas from normotensive versus preeclamptic pregnancies.

Zozzaro-Smith PE, Bushway ME, Gerber SA, Hebert D, Pressman EK, Lord EM, Miller RK, Murphy SP

Placenta.. 2015 November 36 (11):1310-7. Epub 09/10/2015.

Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure.

Gerber SA, Cummings RJ, Judge JL, Barlow ML, Nanduri J, Johnson DE, Palis J, Pentland AP, Lord EM, Ryan JL

Radiation research.. 2015 January 183 (1):72-81. Epub 01/07/2015.

Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.

Martin DK, Uckermann O, Bertram A, Liebner C, Hendruschk S, Sitoci-Ficici KH, Schackert G, Lord EM, Temme A, Kirsch M

Anticancer research.. 2014 July 34 (7):3293-302. Epub 1900 01 01.

Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors.

Gerber SA, Lim JY, Connolly KA, Sedlacek AL, Barlow ML, Murphy SP, Egilmez NK, Lord EM

International journal of cancer.. 2014 May 15134 (10):2383-92. Epub 11/11/2013.

Morphological and phenotypic analyses of the human placenta using whole mount immunofluorescence.

Bushway ME, Gerber SA, Fenton BM, Miller RK, Lord EM, Murphy SP

Biology of reproduction.. 2014 May 90 (5):110. Epub 03/19/2014.

Optogenetic control of chemokine receptor signal and T-cell migration.

Xu Y, Hyun YM, Lim K, Lee H, Cummings RJ, Gerber SA, Bae S, Cho TY, Lord EM, Kim M

Proceedings of the National Academy of Sciences of the United States of America.. 2014 April 29111 (17):6371-6. Epub 04/14/2014.

Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.

Lim JY, Gerber SA, Murphy SP, Lord EM

Cancer immunology, immunotherapy : CII.. 2014 March 63 (3):259-71. Epub 12/20/2013.

G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation.

Majumder S, Sowden MP, Gerber SA, Thomas T, Christie CK, Mohan A, Yin G, Lord EM, Berk BC, Pang J

Arteriosclerosis, thrombosis, and vascular biology.. 2014 February 34 (2):419-26. Epub 11/21/2013.

Radiation therapy combined with -based cancer vaccine synergize to enhance tumor control in the B16 melanoma model.

Lim JY, Brockstedt DG, Lord EM, Gerber SA

Oncoimmunology.. 2014 3 :e29028. Epub 06/03/2014.

Generation of a dual-functioning antitumor immune response in the peritoneal cavity.

Sedlacek AL, Gerber SA, Randall TD, van Rooijen N, Frelinger JG, Lord EM

The American journal of pathology.. 2013 October 183 (4):1318-1328. Epub 08/08/2013.

IFN-? mediates the antitumor effects of radiation therapy in a murine colon tumor.

Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM

The American journal of pathology.. 2013 June 182 (6):2345-54. Epub 04/12/2013.

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM

Immunology.. 2013 March 138 (3):280-92. Epub 1900 01 01.

Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism.

Cummings RJ, Gerber SA, Judge JL, Ryan JL, Pentland AP, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2012 November 1189 (9):4247-57. Epub 09/21/2012.

A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG

Journal of immunological methods.. 2011 October 28373 (1-2):111-26. Epub 08/18/2011.

IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Sorensen EW, Gerber SA, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2010 February 15184 (4):1858-66. Epub 01/08/2010.

Immunology at the university of Rochester.

Lord EM

Immunologic research.. 2009 December 45 (2-3):97-9. Epub 02/25/2009.

Omental immune aggregates and tumor metastasis within the peritoneal cavity.

Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, Lord EM

Immunologic research.. 2009 December 45 (2-3):185-94. Epub 02/28/2009.

Migration of skin dendritic cells in response to ionizing radiation exposure.

Cummings RJ, Mitra S, Foster TH, Lord EM

Radiation research.. 2009 June 171 (6):687-97. Epub 1900 01 01.

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2008 March 1180 (5):3132-9. Epub 1900 01 01.

Antibody-labeled fluorescence imaging of dendritic cell populations in vivo.

Cummings RJ, Mitra S, Lord EM, Foster TH

Journal of biomedical optics.. 2008 13 (4):044041. Epub 1900 01 01.

Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.

Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG

Human gene therapy.. 2007 February 18 (2):93-105. Epub 1900 01 01.

In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.

Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J

Transplantation.. 2007 January 2783 (2):159-66. Epub 1900 01 01.

Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth.

Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM

The American journal of pathology.. 2006 November 169 (5):1739-52. Epub 1900 01 01.

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 2005 June 15174 (12):7516-23. Epub 1900 01 01.

Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.

Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM

The Prostate.. 2005 May 163 (2):105-16. Epub 1900 01 01.

Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.

Moran JP, Gerber SA, Martin CA, Frelinger JG, Lord EM

International journal of cancer.. 2003 September 20106 (5):690-8. Epub 1900 01 01.

Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.

Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM

British journal of cancer.. 2003 May 688 (9):1453-61. Epub 1900 01 01.

Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.

Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG

The Prostate.. 2002 May 1551 (3):153-65. Epub 1900 01 01.

Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.

Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG

Human gene therapy.. 2001 October 1012 (15):1867-79. Epub 1900 01 01.

T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.

Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG

Journal of immunological methods.. 2001 October 1256 (1-2):107-19. Epub 1900 01 01.

Intravascular HBO(2) saturations, perfusion and hypoxia in spontaneous and transplanted tumor models.

Fenton BM, Lord EM, Paoni SF

International journal of cancer.. 2001 September 193 (5):693-8. Epub 1900 01 01.

Tumours can act as adjuvants for humoral immunity.

Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM

Immunology.. 2001 April 102 (4):486-97. Epub 1900 01 01.

Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival.

Fenton BM, Lord EM, Paoni SF

Radiation research.. 2001 February 155 (2):360-8. Epub 1900 01 01.

Alteration of tumour response to radiation by interleukin-2 gene transfer.

Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM

British journal of cancer.. 2000 February 82 (4):937-44. Epub 1900 01 01.

Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation.

Fenton BM, Lord EM, Paoni SF

Radiation research.. 2000 January 153 (1):75-83. Epub 1900 01 01.

Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.

Storozynsky E, Woodward JG, Frelinger JG, Lord EM

Immunology.. 1999 May 97 (1):138-49. Epub 1900 01 01.

Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements.

Fenton BM, Paoni SF, Lee J, Koch CJ, Lord EM

British journal of cancer.. 1999 February 79 (3-4):464-71. Epub 1900 01 01.

Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.

Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG

International journal of molecular medicine.. 1998 October 2 (4):487-96. Epub 1900 01 01.

IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.

Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 1998 June 15160 (12):5773-80. Epub 1900 01 01.

IL-3-mediated enhancement of particulate antigen presentation by macrophages.

Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG

Journal of immunotherapy.. 1998 May 21 (3):205-10. Epub 1900 01 01.

Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.

Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM

Cancer research.. 1998 April 158 (7):1478-85. Epub 1900 01 01.

Tumor immunotherapy: cytokines and antigen presentation.

Lord EM, Frelinger JG

Cancer immunology, immunotherapy : CII.. 1998 April 46 (2):75-81. Epub 1900 01 01.

A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).

Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG

International journal of molecular medicine.. 1998 February 1 (2):379-86. Epub 1900 01 01.

Effect of local irradiation on tumor oxygenation, perfused vessel density, and development of hypoxia.

Fenton BM, Paoni SF, Koch CJ, Lord EM

Advances in experimental medicine and biology.. 1998 454 :619-28. Epub 1900 01 01.

Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth.

Yeh KY, Chen Z, Nasir A, Ohsuga Y, Takashima A, Lord EM, Gaspari AA

The Journal of investigative dermatology.. 1997 December 109 (6):728-33. Epub 1900 01 01.

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1997 June 1094 (12):6369-74. Epub 1900 01 01.

Imaging hypoxia and blood flow in normal tissues.

Koch CJ, Lord EM, Shapiro IM, Clyman RI, Evans SM

Advances in experimental medicine and biology.. 1997 428 :585-93. Epub 1900 01 01.

Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.

Lee J, Siemann DW, Koch CJ, Lord EM

International journal of cancer.. 1996 July 2967 (3):372-8. Epub 1900 01 01.

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.

Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG

Cancer immunology, immunotherapy : CII.. 1996 July 42 (6):362-8. Epub 1900 01 01.

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.

Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG

Proceedings of the National Academy of Sciences of the United States of America.. 1996 April 1693 (8):3669-74. Epub 1900 01 01.

Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.

Woods ML, Koch CJ, Lord EM

International journal of radiation oncology, biology, physics.. 1996 January 134 (1):93-101. Epub 1900 01 01.

Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.

McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM

Cellular immunology.. 1995 October 15165 (2):183-92. Epub 1900 01 01.

B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.

Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM

Cellular immunology.. 1995 October 15165 (2):217-24. Epub 1900 01 01.

Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.

McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG

International journal of cancer.. 1995 May 2961 (5):628-34. Epub 1900 01 01.

Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes.

McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.. 1994 April 15 (3):155-64. Epub 1900 01 01.

Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.

Lord EM, Harwell L, Koch CJ

Cancer research.. 1993 December 153 (23):5721-6. Epub 1900 01 01.

Isolation and expansion of tumor-infiltrating lymphocytes.

Woods ML, McAdam AJ, Frelinger JG, Lord EM

BioTechniques.. 1993 December 15 (6):970-2. Epub 1900 01 01.

Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2.

McAdam AJ, Yeh KY, Pulaski BA, Frelinger JG, Lord EM

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.. 1993 November 14 (4):293-7. Epub 1900 01 01.

Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG

Cancer research.. 1993 May 153 (9):2112-7. Epub 1900 01 01.

Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.

Chen Z, Rosten SI, Lord EM, Gaspari AA

Regional immunology.. 1993 5 (5):285-92. Epub 1900 01 01.

CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.

McAdam AJ, Blieden TM, Frelinger JG, Lord EM

European journal of immunology.. 1992 September 22 (9):2461-4. Epub 1900 01 01.

Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma.

Cerosaletti KM, Woodward JG, Lord EM, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1992 February 15148 (4):1212-21. Epub 1900 01 01.

Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.

Blieden TM, McAdam AJ, Frelinger JG, Lord EM

The Journal of immunology : official journal of the American Association of Immunologists.. 1991 August 15147 (4):1433-8. Epub 1900 01 01.

Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors.

Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger JG, Lord EM

International journal of cancer. Supplement = Journal international

Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.

Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM

Cellular immunology.. 1990 May 127 (2):299-310. Epub 1900 01 01.

Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages.

Wilson KM, Siegal G, Lord EM

Cellular immunology.. 1989 October 1123 (1):158-65. Epub 1900 01 01.

Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle.

Liu YC, Marraccino RL, Keng PC, Bambara RA, Lord EM, Chou WG, Zain SB

Biochemistry.. 1989 April 428 (7):2967-74. Epub 1900 01 01.

Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.

Bahler DW, Cerosaletti KM, Lord EM, Frelinger JG

The Journal of immunology : official journal of the American Association of Immunologists.. 1988 June 1140 (11):4003-12. Epub 1900 01 01.

Cell cycle dependent activities of DNA polymerases alpha and delta in Chinese hamster ovary cells.

Marraccino RL, Wahl AF, Keng PC, Lord EM, Bambara RA

Biochemistry.. 1987 December 126 (24):7864-70. Epub 1900 01 01.

Comparison of fluorescence intensity of Hoechst 33342-stained EMT6 tumour cells and tumour-infiltrating host cells.

Loeffler DA, Keng PC, Wilson KM, Lord EM

British journal of cancer.. 1987 November 56 (5):571-6. Epub 1900 01 01.